【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 7
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q1 2013 9
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q1 2013 9
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q1 2013 11
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q1 2013 12
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q1 2013 13
2.4.1 Biogen Idec To Acquire Elan’s Interest In Multiple Sclerosis Drug Tysabri For $3.25 Billion 13
2.4.2 Medtronic Completes Public Offering of Notes for $3 Billion 13
2.4.3 Cardinal Health to Acquire AssuraMed for up to $2.07 Billion 14
2.4.4 Mylan to Acquire Agila Specialties from Strides Arcolab for up to $1.85 Billion 14
2.4.5 MacroGenics Enters into Licensing Agreement with Gilead Sciences for DART Technology 14
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 15
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q1 2013 15
3.1.1 Top M&A Deals in Q1 2013 16
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q1 2012 – Q1 2013 17
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q1 2013 18
3.2.1 Top Initial Public Offerings in Q1 2013 19
3.2.2 Top Secondary Offerings in Q1 2013 19
3.2.3 Top PIPE Deals in Q1 2013 19
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q1 2012–Q1 2013 20
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2012 – Q1 2013 21
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q1 2013 22
3.3.1 Top Venture Financing Deals in Q1 2013 23
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2013 24
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2013 25
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q1 2012 – Q1 2013 26
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 27
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 28
3.3.7 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q1 2013 29
3.3.8 Top Private Equity Deals in Q1 2013 30
3.3.9 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2012 – Q1 2013 31
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2013 32
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q1 2013 32
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2012 – Q1 2013 34
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2013 35
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2013 36
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2013 36
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q1 2013 37
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 – Q1 2013 38
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q1 2012 – Q1 2013 39
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q1 2012 – Q1 2013 40
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 – Q1 2013 41
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q1 2013 42
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q1 2013 42
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q1 2012 – Q1 2013 43
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2013 44
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q1 2013 44
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2013 45
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2012 – Q1 2013 46
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q1 2012 – Q1 2013 47
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2012 – Q1 2013 48
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q1 2012 – Q1 2013 49
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q1 2012 – Q1 2013 50
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 51
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q1 2012 – Q1 2013 51
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q1 2012 – Q1 2013 52
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q1 2012 – Q1 2013 53
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q1 2012 – Q1 2013 54
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q1 2012 – Q1 2013 55
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q1 2012 – Q1 2013 56
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q1 2012 – Q1 2013 57
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 58
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q1 2013 58
7.1.1 Oncology – Deals of the Quarter 59
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q1 2013 60
7.2.1 Central Nervous System – Deals of the Quarter 61
7.3 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q1 2013 62
7.3.1 Immunology – Deals of the Quarter 63
7.4 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q1 2013 64
7.4.1 Infectious Disease – Deals of the Quarter 65
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q1 2013 66
7.5.1 Metabolic Disorders – Deals of the Quarter 67
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q1 2013 68
7.6.1 Cardiovascular – Deals of the Quarter 69
7.7 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q1 2013 70
7.7.1 Respiratory – Deals of the Quarter 71
7.8 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q1 2013 72
7.8.1 Gastrointestinal – Deals of the Quarter 73
7.9 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q1 2013 74
7.9.1 Ophthalmology – Deals of the Quarter 75
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q1 2013 76
7.10.1 Dermatology – Deals of the Quarter 77
8 Deal Summary by Geography 78
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q1 2013 78
8.1.1 North America – Deals of the Quarter 79
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q1 2013 80
8.2.1 Europe – Deals of the Quarter 81
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q1 2013 83
8.3.1 Asia-Pacific – Deals of the Quarter 84
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q1 2013 85
8.4.1 Rest of the World – Deals of the Quarter 86
9 Pharmaceuticals & Healthcare, Global, Top Advisors 87
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 87
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 88
10 Appendix 89
11 Further Information 92
11.1 Methodology 92
11.2 About GlobalData 93
11.3 Contact Us 93
11.4 Disclosure information 93
11.5 Disclaimer 93
【レポート販売概要】
■ タイトル：事業提携・ライセンシング・投資・M&A動向（四半期別）：Q1 2013■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q1 2013
■ 発行日：2013年4月30日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160890
■ 調査対象地域：グローバル
- 自動車用運転シミュレーター世界市場2017-2021ABSTRACTAbout Automotive Driving Simulator Driving simulators, also called as sims, are a class of human-machine interfaces (HMIs), which are used to imitate the exact or near-exact conditions prevalent during driving, with respect to the driver's perspective, motion and physics perspective, as well as the vehicle interior and exterior perspective. Technavio’s analysts forecast the global automoti …
- トレーシール機の世界市場2018-202299 pages, November 2018 About this market Tray sealing machinery manufacturers are investing heavily in research and development to upgrade their products with new features. For instance, ProMach introduced several new tray sealing solutions under the brand name Ossid in 2016. The vacuum skin pack/modified atmosphere packaging feature of its OTS-10VMAP tabletop tray sealer ensures a longer shelf l …
- 血行動態モニタリング装置（医療機器）のグローバル市場（2012-2018）Global Hemodynamic Monitoring Devices sector is projected to reach US$1.3 billion by 2016. The North America accounts for nearly 32% (2015) of the global share while Europe claims approximately 29% (2018). Asia-Pacific is the fastest growing region with a CAGR of 27.3% driving a market value of US$283 million by 2015. On a global scale, projections for Cardiac Output Monitoring Devices indicate mo …
- 不眠症治療のグローバル臨床試験動向（2014年H2）Insomnia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Insomnia Global Clinical Trials Review, H2, 2014" provides data on the Insomnia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Insomnia. It includes an overview of the trial numbers and their recruitment status as per the site of trial condu …
- 自動車ガスケット及びシールの世界市場：金属ガスケット、非金属ガスケット、Oリングシール、リップシール、ロータリシール、メカニカルシールGaskets and Seals are vital components in a vehicle, which are used for filling the gap between two components to ensure that there is no leakage between them during the compression stage. Over a period of time, technological advancements have made automotive gasket and seal safer and more effective. The materials used in gasket fabrication have improved over the time; silicone rubber has become a …
- Essent N.V.：石油・ガスバリューチェーン分析レポート2013Essent N.V. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Essent N.V." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Essent N.V.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines the company’s business …
- 世界のヘッドアップディスプレイ（HUD）市場動向（2012-2016）TechNavio's analysts forecast the Global Heads-up Display market to grow at a CAGR of 14.32 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing focus on improving safety and convenience for drivers/pilots of various vehicles. The Global Heads-up Display market has also been witnessing declining average selling prices (ASPs). However, the c …
- 世界のコネクテッドカー市場2015-2025The increased demand for wireless connectivity, demonstrated by the high level of penetration of smartphones and tablets, drives the automotive industry to adjust to a new lifestyle consensus and incorporate in-vehicle internet connectivity solutions. Moreover, global regulatory mandates (eCall in EU, GLONASS in Russia, Contran 245 in Brazil) require the usage of telematics for safety purposes and …
- 世界の商用航空機ウィンドウ及びフロントガラス市場動向（2012-2016）TechNavio's analysts forecast the Global Commercial Aircrafts Windows and Windshields market to grow at a CAGR of 3.33 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for aircrafts in the APAC region. The market has also been witnessing an increasing demand for low-maintenance aircraft windows. However, the increasing price of r …
- 事業提携・ライセンシング・投資・M&A動向（四半期別）：Q2 2013Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2013 Summary GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2013” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides …
- A.P. Moller – Maersk A/S：石油・ガスバリューチェーン分析レポート2013A.P. Moller - Maersk A/S Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "A.P. Moller - Maersk A/S" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “A.P. Moller - Maersk A/S”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The …
- 世界のサイクロスポーラ検査市場The report presents a detailed analysis of the Cyclospora diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cyclospora definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- イギリスの高圧コンデンサ市場：主要用途、ドライバー、トレンドHigh Voltage Capacitors in the UK: Key Applications, Drivers and Emerging Trends Summary With the sharp increase in investment in distributed intermittent generators and High Voltage (HV) power consuming industrial facilities along with the need for ultra-HV lines; shunt reactors and series capacitors have become essential electrical equipment for the management of global power systems. There has …
- LBC Tank Terminals：石油・ガスバリューチェーン分析レポート2013LBC Tank Terminals Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "LBC Tank Terminals" Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “LBC Tank Terminals”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines t …
- 世界のセキュリティ及び監視レーダー市場動向及び予測（2014 – 2020）The report analyzes the surveillance and security radar market, illustrating information about trend analyses in the market with reference to technology, geography, and countries. The report discusses the market drivers and restraints that sway the market for investment in the defense as well as civil segments. It further talks about the challenges and opportunities that provide probable growth as …
